Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials is a research paper published in Clinical Infectious Diseases (2021). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Allergy and Infectious Diseases
Grant: UM1-AI068634
Wellcome Trust
Grant: 203135/Z/16/Z
Wellcome Trust
Grant: 104803
National Institutes of Health
Grant: K43TW011421
NIAID NIH HHS
Grant: UM1 AI068634
Wellcome Trust
Grant: 203135
LEVERAGING CESGA TO RESEARCH CENTER OF EXCELLENCE
National Institutes of Health
Grant: 5UM1AI068634-09
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
National Institutes of Health
Grant: 1K43TW011421-01
Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitis
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Methods for handling missing data in serially sampled sputum specimens for mycobacterial culture conversion calculation
Additional file 1 of Methods for handling missing data in serially sampled sputum specimens for mycobacterial culture conversion calculation
Additional file 2 of Methods for handling missing data in serially sampled sputum specimens for mycobacterial culture conversion calculation
Additional file 2 of Methods for handling missing data in serially sampled sputum specimens for mycobacterial culture conversion calculation